Neurogene Inc.

NGNE | NASDAQ

Price Alert Chart Builder DCF Calculator

$32.57

+$0.48 (+1.50%)

At close: Sep 21, 2026, 4:00 PM ET

$32.57

$0 (0.00%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.50%

(1D)

Rating

Updated: Sep 19, 2026

15.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $514.68M

1D Range

31.18 32.85

52W Range

15.93 43.66

Valuation (TTM)

PE -5.91

PB 2.37

EV/EBITDA -2.80

Valuation (NTM)

Forward PE N/A

Forward PEG 2.03

Price Target $72

Cash Flow

FCF Yield -16.9%

SBC Adj. FCF Yield -18.4%

SBC Impact -9.0%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -150.0% | 0.0%

Dil EPS 3Y | 5Y -124.2% | -39.1%

FCF 3Y | 5Y -5.1% | -16.9%

Returns

ROA -45.5%

ROE -45.1%

ROIC -53.7%

Financial Health

Net Cash

$225.39M

Current Ratio 10.64

Interest Coverage -60,673.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently fe...

Sector Healthcare

Industry Biotechnology

Employees 131

IPO Date Mar 6, 2014

Website www.neurogene.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$70

Upside

+114.92%

Buy (3)

Hold (0)

Sell (0)

Analyst Details ➞